Cigna’s Evernorth Introduces Two Programs To Manage GLP-1 Drugs For Diabetes & Weight Loss

Evernorth, a subsidiary of The Cigna Group, is launching two new programs intended to help consumers and plan sponsors manage the costs and delivery of GLP-1 drugs prescribed for people with type 2 diabetes or obesity. The new programs are intended to ensure that plan sponsors achieve the most value by ensuring that the right consumers receive the medications and that consumers receive sufficient clinical support to use them correctly.

The two new programs are Evernorth EnReachRx to provide pharmacy support for dispensing GLP-1 prescriptions and Evernorth EnGuide Pharmacy to manage home deliveries. The EnReachRx suite of solutions . . .